Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 4/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156737 | 0.84 | DAO (0.53) | PNMTDAOHTR2BHTR2AHTR2C | |
| SCHEMBL4429682 | 0.83 | PNMT (0.55) | PNMTDAOHTR2BHTR2AHTR2C | |
| SCHEMBL474177 | 0.83 | PNMT (0.55) | PNMTDAOHTR2BHTR2AHTR2C | |
| SCHEMBL30705300 | 0.83 | PNMT (0.55) | PNMTDAOHTR2BHTR2AHTR2C | |
| SCHEMBL255035 | 0.83 | PNMT (0.55) | PNMTDAOHTR2BHTR2AHTR2C | |
| SCHEMBL2601113 | 0.83 | DAO (0.59) | PNMTDAOHTR2BHTR2AHTR2C | |
| SCHEMBL23343776 | 0.82 | PNMT (0.53) | PNMTDAOHTR2BHTR2AHTR2C | |
| SCHEMBL1653852 | 0.82 | HDAC8 (0.41) | PNMTDAOTSHR | |
| SCHEMBL7336199 | 0.82 | PNMT (0.53) | PNMTDAOHTR2BHTR2AHTR2C | |
| Ammonia Solution, Strong SCHEMBL27629775 | 0.82 | PNMT (0.53) | PNMTDAOHTR2BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4568968-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Remynd N.V. (BE) | 2025-06-18 | — | — | EP | disclosed |
| EP-4568965-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4558224-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-05-28 | — | — | EP | disclosed |
| CN-115872930-B | N-substituted 3, 4-dihydro-isoquinolin-1 (2H) -one derivatives, compositions thereof and use thereof in medicine | 贵州医科大学 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024033454-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
| CN-1882588-A | A2B adenosine receptor antagonists | CV THERAPEUTICS INC (US) | 2006-12-20 | — | — | CN | disclosed |
| WO-2006107257-A1 | NOVEL 5,7-DISUBSTITUTED [1,3]THIAZOLO[4,5-D]PYRIMIDIN-2(3H)-ONE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006107258-A1 | NOVEL 5-SUBSTITUTED 7-AMINO-[1,3]THIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| CN-1777427-A | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN INC (US) | 2006-05-24 | — | — | CN | disclosed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2006021886-A1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-4185992-A | Imidazole derivatives | MAY & BAKER LIMITED (GB) | 1980-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055113-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CLIC1 | PNMT 4334/4885DAO 2757/4885HTR2B 2917/4885 |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | ALK, MET, ERBB2 | PNMT 603/4885DAO 1331/4885HTR2B 1314/4885 |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, CDC42BPA | PNMT 701/4885DAO 286/4885HTR2B 3270/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | PNMT 4171/4885DAO 3685/4885HTR2B 1673/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | PNMT 286/4885DAO 344/4885HTR2B 590/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | PNMT 1734/4885DAO 4181/4885HTR2B 4217/4885 |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, CHRNA6, CHRNA5 | PNMT 1775/4885DAO 2142/4885HTR2B 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.